Taysha Gene Therapies, Inc. Property, Plant and Equipment
Taysha Gene Therapies, Inc. (TSHA) had Property, Plant and Equipment of $2.41 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentNet · last filed 2026-08-11
- 2026-06-30: Property, Plant and Equipment, Net $2.41M.
- 2026-03-31: Property, Plant and Equipment, Net $6.45M.
- 2025-12-31: Property, Plant and Equipment, Net $6.74M.
- 2025-09-30: Property, Plant and Equipment, Net $6.80M.
| Period end | Property, Plant and Equipment, Net |
|---|---|
| 2026-06-30 | $2.41M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $6.45M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $6.74M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $6.80M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $6.96M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $7.24M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $7.49M 10-K · filed 2026-03-19 |
| 2024-09-30 | $7.61M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $10.51M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $10.69M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $10.83M 10-K · filed 2025-02-26 |
| 2023-09-30 | $11.17M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $14.14M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $14.64M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $14.96M 10-K · filed 2024-03-19 |
| 2022-09-30 | $63.95M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $61.01M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $55.12M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $50.61M 10-K · filed 2023-03-28 |
| 2021-09-30 | $40.55M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $33.87M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $2.50M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $287.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $28.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |